ERBB2 and prostate carcinoma: MiR-331-3p has been shown to suppress ERBB2 signaling in prostate cancer [31] while ERBB-2 was indicated to be correlated with chemoradiation therapy resistance in muscle invasive bladder cancer patients [32].